Free delivery on orders over £40 Oral weight loss is here UK-registered prescribers, GPhC regulated Free delivery on orders over £40 Oral weight loss is here UK-registered prescribers, GPhC regulated Free delivery on orders over £40 Oral weight loss is here UK-registered prescribers, GPhC regulated

Wegovy Tablet Approved in the UK

Date: 12 / Jun / 2026

Wegovy Tablet Approved in the UK: The Ultimate Guide 2026
Clinically Reviewed
Written and clinically reviewed by Muhammad Mian MPharmS IP, Superintendent Pharmacist and Independent Prescribing Pharmacist, GPhC Reg. 2066548  |  Last reviewed: 12 June 2026

On 11 June 2026, the MHRA approved the Wegovy tablet (oral semaglutide) for weight management, the first daily GLP-1 weight loss pill ever licensed in the UK. The headlines write themselves, but if you are actually considering treatment, the headlines do not answer the question that matters: should you wait for the Wegovy tablet, or start treatment now? As a prescribing pharmacist, this is the question I expect to be asked most over the coming months, by people who have been putting off treatment because of needles, and by existing patients wondering whether to switch. This guide gives you a straight answer: what the Wegovy tablet is, how well it works, what the daily routine genuinely involves, who can switch directly from the injection, and how to decide what is right for you.

Wegovy tablet UK: the key facts

  • Approved by the MHRA on 11 June 2026 for weight management in adults
  • Contains semaglutide, the same active ingredient as the Wegovy injection
  • Taken once daily; doses are 1.5mg, 4mg, 9mg, then 25mg maintenance
  • Average weight loss of around 13.6% at 64 weeks in the OASIS 4 trial, around 16.6% with full adherence
  • Must be taken on an empty stomach after an overnight fast, then nothing to eat or drink for at least 30 minutes
  • Patients on the 2.4mg weekly Wegovy injection can transition directly to the 25mg tablet
  • UK launch date and pricing are not yet confirmed by Novo Nordisk

What exactly has the MHRA approved?

The MHRA has licensed the Wegovy tablet, a once daily oral form of semaglutide made by Novo Nordisk, for weight loss and weight management. It can be prescribed to adults living with obesity (a BMI of 30 or above), or adults who are overweight (a BMI of 27 to under 30) with at least one weight-related health condition, such as high blood pressure, high cholesterol, or sleep apnoea. As with every GLP-1 medicine, it is licensed for use alongside a reduced calorie diet and increased physical activity, not as a replacement for them.

Semaglutide has existed as a tablet for several years under the brand name Rybelsus, but only at lower doses and only for type 2 diabetes. The Wegovy tablet is different: it goes up to a 25mg daily maintenance dose, the level shown in trials to deliver weight loss comparable to the weekly injection. The UK is the third country to approve it, after the United States and the United Arab Emirates.

How effective is the Wegovy tablet?

The approval is based on OASIS 4, a phase 3 trial of the 25mg Wegovy tablet in 307 adults living with obesity, or overweight with a weight-related condition, who did not have diabetes. After 64 weeks alongside lifestyle changes, participants taking the tablet lost on average around 13.6% of their body weight, compared with around 2.4% on placebo. Among participants who took the treatment exactly as intended, average weight loss reached around 16.6%, versus around 2.7% with placebo.

Notice the gap between those two figures. The difference between 13.6% and 16.6% is largely about adherence: people who followed the strict dosing routine absorbed more of the medicine and lost more weight. That tells you something important about the Wegovy tablet before you ever take it. Its results depend on your routine in a way the injection’s simply do not. Side effects were familiar territory: mostly gastrointestinal, with around 7% of participants stopping treatment because of adverse events, in line with injectable semaglutide.

The daily routine: what taking the Wegovy tablet actually involves

This is the part most coverage glosses over, and the part I want to be completely honest about. Semaglutide is a peptide, and peptides are normally destroyed by stomach acid, which is why GLP-1 medicines have historically been injections. The Wegovy tablet uses an absorption enhancer to get semaglutide through the stomach lining, and that technology only works under strict conditions:

  • Take one tablet on an empty stomach after fasting for at least 8 hours, which for most people means first thing in the morning
  • Swallow it whole with a sip of plain water: never with any other drink, and never split, crushed, or chewed
  • Wait at least 30 minutes before any food, any other drink, or any other oral medicines
  • If you miss a dose, skip that day and take your next dose at the usual time; never double up
  • Store the tablets in their original closed bottle, protected from moisture

If your mornings are calm and consistent, this is a 30 minute habit that quickly becomes automatic. If your mornings are chaotic, shift work for example, or an early gym session with a pre workout drink, or medication you must take with breakfast, then the Wegovy tablet will demand real changes to your routine, and skipping the routine quietly erodes your results. This is the honest trade off: the injection asks for one moment of discipline a week, the tablet asks for a small one every single day.

Wegovy tablet dosing: how prescribing will work

The Wegovy tablet comes in four strengths: 1.5mg, 4mg, 9mg, and 25mg. Everyone starts at 1.5mg once daily, with the dose increased step by step and a minimum of one month at each level before moving up, as tolerated, to the 25mg maintenance dose. This mirrors the approach used with the injections, and it exists for the same reason: gradual escalation keeps nausea and other digestive side effects manageable while your body adjusts.

Already on the Wegovy injection? You can switch directly

One provision in the licence will matter to a lot of our patients: people established on the 2.4mg weekly Wegovy injection can transition straight to the 25mg daily Wegovy tablet, without restarting the dose ladder from the bottom, subject to clinical assessment. So if you start or continue injectable treatment today, you are not locking yourself out of the tablet. When it launches, switching is a conversation with our prescriber, not a restart. That single fact changes the wait or start question considerably, and we come back to it below.

Wegovy tablet vs Wegovy injection vs Mounjaro

Wegovy tabletWegovy injectionMounjaro
Active ingredientSemaglutide (GLP-1)Semaglutide (GLP-1)Tirzepatide (GLP-1 and GIP)
How it is takenOne tablet daily, strict fasting routineOne injection weekly, any time, with or without foodOne injection weekly, any time, with or without food
Average trial weight lossAround 13.6% to 16.6% at 64 weeks (OASIS 4)Around 15% at 2.4mg; up to around 20% at the new 7.2mg doseAround 20% or more at higher doses
Availability at EverslimAwaiting UK launchAvailable nowAvailable now

The honest reading of the evidence: Mounjaro currently has the strongest average trial results of the three, which is why it remains the most popular first choice among eligible patients. Between the two forms of Wegovy, the choice is about lifestyle rather than effectiveness: the tablet trades the needle for a daily routine, the injection trades a weekly needle for total flexibility. There is no wrong answer, only a right answer for your circumstances, and that is exactly what a consultation is for.

When can you get the Wegovy tablet in the UK, and what will it cost?

Novo Nordisk has indicated plans to launch the Wegovy tablet in selected markets during the second half of 2026, but the confirmed UK launch date and UK pricing have not been announced, and we will not speculate on either. On NHS availability, MHRA approval is only the first step: NHS funding would require a separate cost effectiveness assessment by NICE, and even the Wegovy injection remains restricted on the NHS to specialist weight management services with strict criteria and long waits. Realistically, regulated private pharmacies like Everslim are expected to be the first route of access for the Wegovy tablet, exactly as they were for the injectable treatments. As an NHS registered pharmacy group operating for over 15 years, with every order reviewed by our Independent Prescribing Pharmacist, we will stock it as soon as UK supply is confirmed, and we will publish transparent pricing the moment we have it.

So, should you wait for the Wegovy tablet or start now?

Here is the framework I will be using with my own patients.

Starting now makes sense for most people

If you are eligible for treatment, there is no clinical reason to delay. The launch date for the Wegovy tablet is unconfirmed, and every month spent waiting is a month of progress not made: in OASIS 4 terms, participants were already several kilograms down within the first few months of treatment. Crucially, starting on an injection now does not cost you the tablet later. If you begin Wegovy today, the licence allows a direct transition from the 2.4mg injection to the 25mg tablet when it arrives. If you begin Mounjaro and it suits you, you may find, as many patients do, that the question of switching simply stops mattering once the results are coming.

Waiting makes sense in one situation

If a genuine needle phobia is the single thing that has kept you from starting, and no amount of reassurance about how small the needle is changes that, then the Wegovy tablet is the option designed for you, and waiting is a legitimate choice. Use the time well: the medicines work best on top of solid foundations, so spend the months before launch building the habits around food, movement, and sleep that will make the tablet far more effective when you start it.

Not sure which treatment fits your life?

Complete a free online consultation and our prescribing pharmacist will recommend the right option for you, including whether it is worth waiting for the tablet.

Start Your Free ConsultationCompare Treatments

Wegovy tablet FAQs

Is the Wegovy tablet as effective as the Wegovy injection?

Broadly, yes. The 25mg Wegovy tablet produced average weight loss of around 13.6% to 16.6% over 64 weeks in OASIS 4, in line with the roughly 15% seen with the standard 2.4mg injection in its trials. The key difference is that the tablet’s results depend on following the strict empty stomach routine every day.

Is the Wegovy tablet the same as Rybelsus?

They both contain oral semaglutide, but they are not interchangeable. Rybelsus is licensed for type 2 diabetes at lower doses. The Wegovy tablet is licensed specifically for weight management and goes up to a 25mg daily dose.

Can I have coffee or breakfast after taking the Wegovy tablet?

Not straight away. You must wait at least 30 minutes after taking the tablet before any food or drink other than the sip of water you swallow it with, and before any other oral medicines. Taking it with food or other drinks significantly reduces how much semaglutide is absorbed.

Will the Wegovy tablet be available on the NHS?

Not initially. MHRA approval licenses the medicine but does not fund it; NHS availability would depend on a NICE assessment, and NHS access to weight loss treatments is currently limited to specialist services. Regulated private pharmacies are expected to be the first route of access in the UK.

Who is eligible for the Wegovy tablet?

Adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition such as high blood pressure, high cholesterol, or sleep apnoea. As with all our treatments, eligibility is confirmed through an online consultation reviewed by our prescribing pharmacist.

The bottom line from our prescriber

The Wegovy tablet is a genuinely important approval: the first daily GLP-1 pill in the UK, with results comparable to the injection it is based on. It is not a stronger medicine, and it is not an easier one; it simply removes one barrier (the needle) and adds another (a disciplined daily routine). For most eligible people, the best move is still to start treatment now with Mounjaro or Wegovy, knowing the door to the tablet stays open. For the minority for whom needles are the dealbreaker, the Wegovy tablet is worth the wait, and we will be ready for you on day one. Either way, the right starting point is the same: a free, no obligation online consultation with our clinical team.

The Wegovy tablet is a prescription only medicine. Treatment is subject to an online consultation and is only supplied where our Independent Prescribing Pharmacist decides it is clinically appropriate. GLP-1 medicines must be used alongside a reduced calorie diet and increased physical activity, under ongoing clinical supervision. Information in this article is correct as of 12 June 2026 and will be updated when UK launch details, prescribing information, and pricing are confirmed.

 

Ready to Take the Next Step? Start Your Weight Loss Journey Today!

Take our short 5 minute questionnaire now.